ChromaDex Reports FDA's Conclusion that Nicotinamide Mononucleotide (NMN) May Not Be Sold or Marketed as a Dietary Supplement in the United States

Author's Avatar
Nov 11, 2022

ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, today announced that on November 4, 2022, the U.S. FDA declared nicotinamide mononucleotide (NMN) may no longer be sold or marketed as a dietary supplement in the United States since it was first investigated as a drug.